Pacira Pharmaceuticals, Inc.

Form 4

August 08, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005 Estimated average

OMB APPROVAL

3235-0287

burden hours per response... 0.5

OMB

Number:

Section 16. Form 4 or Form 5 obligations may continue. See Instruction

Check this box

if no longer

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * PATOU GARY			2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer			
(Last) (First) (Middle)		(Middle)	Pacira Pharmaceuticals, Inc. [PCRX] 3. Date of Earliest Transaction	(Check all applicable)			
C/O MPM ASSET MANAGEMENT, 601 GATEWAY BLVD., SUITE 350			(Month/Day/Year) 08/07/2014	Director 10% Owner Something of the control of th			
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
SOUTH SAN		0		Form filed by More than One Reporting Person			

FRANCISCO, CA 94080

(City)	(State)	(Zip) Tab	le I - Non-I	Derivative	red, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired (A) Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/07/2014		M <u>(1)</u>	1,230	A	\$ 1.61	1,230	D	
Common Stock	08/07/2014		M <u>(1)</u>	882	A	\$ 5.49	2,112	D	
Common Stock	08/07/2014		M(1)	14,364	A	\$ 10.81	16,476	D	
Common Stock	08/07/2014		M(1)	3,524	A	\$ 11.68	20,000	D	
	08/07/2014		S(1)	20,000	D		0	D	

Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Common	\$
Stock	100.26
	(2)

Common Stock 702 I Footnote $\frac{3}{(3)}$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 1.61	08/07/2014		M(1)		1,230	<u>(4)</u>	09/02/2020	Common Stock	1,230
Stock Option (Right to Buy)	\$ 5.49	08/07/2014		M(1)		882	<u>(5)</u>	12/29/2020	Common Stock	882
Stock Option (Right to Buy)	\$ 10.81	08/07/2014		M <u>(1)</u>		14,364	<u>(6)</u>	06/05/2022	Common Stock	14,364
Stock Option (Right to Buy)	\$ 11.68	08/07/2014		M(1)		3,524	<u>(7)</u>	06/07/2022	Common Stock	3,524

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners 2

Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Director 10% Owner Officer Other

PATOU GARY C/O MPM ASSET MANAGEMENT 601 GATEWAY BLVD., SUITE 350 SOUTH SAN FRANCISCO, CA 94080

Chief Medical Officer

Signatures

/s/ Gary Patou 08/07/2014

**Signature of Pate Pate Date Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction was pursuant to a 10b5-1 Plan dated March 11, 2014.
- Represents weighted average sales price. The shares were sold at prices ranging from \$100.00 to \$100.28. The Reporting Person will provide upon request, to the SEC, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price.
- (3) Shares held by Patou Family Trust, of which the reporting person is trustee.
- (4) 25% of the option shares vested on September 2, 2011 and the remaining 75% of the option shares vest monthly over the next 36 months. The option shares become exercisable when vested.
- (5) 25% of the option shares vested on December 29, 2011 and the remaining 75% of the option shares vest monthly over the next 36 months. The option shares become exercisable when vested.
- (6) 25% of the option shares vested on June 5, 2013 and the remaining 75% of the option shares vest monthly over the next 36 months. The option shares become exercisable when vested.
- (7) 25% of the shares vest on June 7, 2013 and the remainder of the shares vest monthly over the following 36 months. The option shares become exercisable when vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3